The purpose of this study is to compare the incidence rates of targeted infections, malignancies and mortality among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications.
Study Type
OBSERVATIONAL
Enrollment
20,000
Key safety outcomes (targeted infections, malignancies, mortality)
Time frame: Every 6 months throughout the study
Patient-reported infusion reactions
Time frame: Every 6 months throughout the study
Multiple sclerosis, lupus, and psoriasis
Time frame: Every 6 months throughout the study
Adverse events in pregnant women who receive abatacept
Time frame: Every 6 months throughout the study
Adverse events in subjects on abatacept who receive concomitant biologics
Time frame: Every 6 months throughout the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.